This synergistic approach, combining in silico methods for rapid hypothesis generation with experimental validations, was designed to increase confidence in Antrocin’s therapeutic potential and advance its development as a novel agent for the management of colorectal cancer by targeting the BRAF/MEK/PI3K tumor proliferative axis and overcoming drug resistance. This evidence concerns the gene PIK3CA and neoplasm.